Hi and welcome to the A16Z podcast. I'm Hannah. This episode is all about the new medical

paradigm of CAR-T therapy, a new cancer treatment that uses engineered T cells to attack cancer

and has been so effective in treating childhood leukemia's, we believe it may actually be a cure.

In this conversation, Timmunity CEO Oz Azam discusses with general

partner Jorge Condi and myself all about what CAR-T therapy is and how it all works, starting with the

patient and cell journey to how this medicine is developed, manufactured, delivered to patients,

how different it is to traditional medicines,

and then what it will take to make these new treatments work on more kinds of cancer,

scale to more patients, and be more affordable.

And finally, what company building lessons can be learned from having built the first

car tea company of this kind from the ground up?

This episode was recorded at the

annual A16Z summit. We're here to talk about this new kind of therapy, CAR-T therapy, and what it

means to be building a company that is delivering this brand new medical paradigm for cancer

treatment. So let's just start by giving a little bit of background.

What is your tagline of here's what CART is? So CART is also known as chimericantogen receptor therapies.

Nature's biggest gift that we were given in terms of protecting us from disease is something called

T cells. There are a subset of your blood cells that are called white cells.

White cells typically prevent infection disease.

So they are always surveilling and protecting you.

A B-cell produces antibodies.

A T-cell actually hones in and gobbles up peptides and abnormalities that are circulating in the

...